Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLX105 Hydrogel
- Development stage
- Phase 2
- Lead developer
- Delenex
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical, Intradermal
01
Overview
DLX105 Hydrogel is a topical formulation containing DLX105, a single-chain anti-TNF-α antibody fragment. It is designed for the treatment of mild to moderate plaque psoriasis through local inhibition of TNF-α, a key inflammatory cytokine involved in psoriasis pathogenesis. The hydrogel formulation allows for topical application directly to psoriatic plaques, potentially providing targeted therapy without systemic effects.
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on DLX105 Hydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLX105 Hydrogel.